NASDAQ · COCH
Envoy Medical, Inc.
$6.50-$0.16 (-2.4%)
Envoy Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.87% below the high.
Loading market information…
NASDAQ · NVNO · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
enVVeno Medical Corporation’s quoted price sits in the lower half of its reported 52-week range, 73.37% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow enVVeno Medical Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:53 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00-100.0% vs estimate |
| Q1 2025 | Apr 30, 2025 | -$7.70+35.29% vs estimate | $0.00-100.0% vs estimate |
|---|
| Q4 2024 | Feb 28, 2025 | -$0.350.0% vs estimate | $0.00-100.0% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$6.50-$0.16 (-2.4%)
Envoy Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.87% below the high.
$15.90-$1.74 (-9.86%)
Ekso Bionics Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 40.14% below the high.
$1.98+$0.01 (+0.51%)
Aytu BioPharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 35.5% below the high.
$0.40-$0.05 (-10.49%)
Co-Diagnostics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.41% below the high.
$5.52-$0.03 (-0.54%)
Aethlon Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.6% below the high.
$0.09-$0.02 (-18.94%)
Adagio Medical Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.91% below the high.
$0.19-$0.01 (-6.25%)
GeoVax Labs, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.72% below the high.
$0.12-$0.00 (-1.07%)
Vivos Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.57% below the high.
